Free Submission Public Relations &
Deutsch English


Families Carry a Major Burden of the Diabetes Pandemic, According to New Results from Global Study

Print article Print article
© Marketwire 2012
2012-12-03 15:00:57 -

COPENHAGEN, DENMARK -- (Marketwire) -- 12/03/12 -- Today, the initial results of Diabetes Attitudes, Wishes and Needs 2 (DAWN2(TM)) study were announced. DAWN2(TM) examines the psychosocial aspects of diabetes management for people living with diabetes, their families and their healthcare providers. It is the largest study of its kind, conducted across 17 countries and 4 continents.
"The DAWN2(TM) study confirms that the physical, financial and emotional burden of diabetes across cultures and countries is carried by the entire family, not just by the person with diabetes", says Professor Mark Peyrot, principal investigator and chair of the international scientific committee overseeing the DAWN2(TM) study.
For the first time in the DAWN(TM) study program, family members were surveyed - along with people with diabetes, nurses, dieticians, general practitioners and specialists - to find new ways of reducing the burden of the condition.

"The results of the DAWN2(TM) will be welcomed with great interest by Canadians living with diabetes, their families and healthcare professionals," says Dr. Michael Vallis, registered clinical psychologist and Associate Professor, Family Medicine and Psychiatry and Adjunct Professor, Psychology, Dalhousie University. "With Canadian-specific results, we will gain new insights into the personal and often complex issues faced not only by the individual living with diabetes, but also their loved ones and healthcare professionals who play an integral role in supporting their diabetes management."
The initial results for Canada show that:

--  58% of family members are anxious about the possibility that the person
    they live with will develop serious complications from the condition 
--  51% of family members of insulin-treated people with diabetes fear that
    their loved one will become hypoglycaemic during the night 
--  30% of family members report a negative financial impact on themselves
    due to the diabetes of their loved one 
--  12% of family members experience that their loved one is being
    discriminated against because of diabetes and that the community they
    live in is intolerant of diabetes 
--  25% of people with diabetes report their family argues with them about
    how they manage their diabetes 
--  60% of family members have not attended an education programme about
    diabetes, despite at least 70% of diabetes healthcare professionals
    believe that involvement of family members is a vital part of good
    diabetes care.

"The DAWN2(TM) study brings new and important scientific data about the hidden burden of the diabetes pandemic on the families of people with diabetes and the gaps in current healthcare systems. The societal implications of these findings are significant and DAWN2(TM) results should motivate and compel decision-makers, healthcare providers and patient organisations to act in unity to improve education and support for both people with diabetes and their loved ones," says Sir Michael Hirst, President Elect of the IDF.
DAWN2(TM) is a global Novo Nordisk initiative conducted in collaboration with the International Diabetes Federation (IDF), the International Alliance of Patient Organisations (IAPO), the Steno Diabetes Center and a range of other national, regional and global partners.
"DAWN2(TM) represents our company's long-term commitment to work in partnership to improve the lives of people with diabetes," explains Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk. "Even with the best available medicines, people with diabetes depend on diabetes education and day-to-day motivation and support from family, friends and the wider society."
DAWN2(TM) expands on the original DAWN(TM) study from 2001 and involves people with diabetes, their families, carers and a wide range of diabetes healthcare professionals as well as patient organisation and diabetes policy experts. The DAWN2(TM) study is the voice of more than 15,000 persons living with or caring for people with diabetes in 17 countries across 4 continents.
The three main objectives of the DAWN2(TM) initiative are to:

--  advance understanding and awareness of the unmet needs of people with
    diabetes and their families 
--  facilitate dialogue and collaboration to strengthen patient involvement
    and improve self-management and psychosocial support in diabetes care 
--  to establish international scientific benchmarking system for person-
    centred diabetes care and health policy. 

The DAWN2(TM) study was conducted during 2012 and will be followed by a comprehensive programme of activities until at least 2016. The results of DAWN(TM)2 will be published in a series of articles starting in the spring of 2013. Additionally, partnership actions will be identified on a global and local level to address the critical needs and gaps identified by the study.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit : .
Mark Peyrot et al on behalf of the Global DAWN2 (Diabetes Attitudes Wishes and Needs) Study Group: A multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Accepted for Publication, Diabetes Research and Clinical Practice, 2012.



Charlotte Zarp-Andersson

+45 3079 7603 :

Jeremy Brace (Canada)

+1 905 629 6241 :


Kasper Roseeuw Poulsen

+45 4442 4303 :

Frank Daniel Mersebach

+45 4442 0604 :

Lars Borup Jacobsen

+45 3075 3479 :

Jannick Lindegaard (US)

+1 609 786 4575 :

Press Information:

Contact Person:

Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact